NurOwn Dosing Likely to Continue for ALS Patients in Its EAP

NurOwn Dosing Likely to Continue for ALS Patients in Its EAP

315172

NurOwn Dosing Likely to Continue for ALS Patients in Its EAP

Amyotrophic lateral sclerosis (ALS) patients who completed the expanded access protocol (EAP) for NurOwn may soon be eligible for three additional doses of the cell-based therapy, BrainStorm Cell Therapeutics reported. EAPs, also known as compassionate use programs, are intended to make investigational therapies available outside of a clinical trial to people whose serious or life-threatening conditions have few or no adequate treatments, when the therapy’s benefits are thought to outweigh potential risks. The company launched an…

You must be logged in to read/download the full post.